MedTrace Logo

A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease

NCT01944436 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 57

Last updated 2016-04-13

No results posted yet for this study

Summary

Lewy body spectrum disorders are a common group of neurodegenerative diseases that cause memory loss, behavioural and motor disabilities that impair quality of life. Cognitive enhancers help people afflicted with these conditions. However, some people do not benefit from this treatment, while others experience serious side effects. Side effects and poor response lead to hospitalization and early institutionalization. Pharmacogenomics, the study of how DNA variation can influence drug effects, will be combined with functional changes in brain imaging in response to cognitive enhancers in patients with Lewy body disease. The goal is to develop a predictive test that can be administered in the clinic to aid physicians' choice of initial medication. This can reduce health care costs and improve treatment to Canadians suffering from these devastating disorders.

Conditions

  • Lewy Body Disease

Interventions

DRUG

Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01944436 on ClinicalTrials.gov